catalyst

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olan — primary completion

as of 2026-07-01
at a glance
2026-06 · Estimated (est.)Registry-estimated date, not yet actual.
Synthesized from structured facts only — each point cited above.

Event

What
Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olan — primary completion
Type
Trial Readout
Date
2026-06
Date type
ESTIMATED est.
Phase
Phase 3
Registry-estimated date, not yet actual. This date is directional and must not be read as settled.